Posted by Michael Wonder on 14 Nov 2016
European Commission approves Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults on haemodialysis
11 November 2016 - First treatment advance for secondary hyperparathyroidism in more than a decade and first intravenous calcimimetic to help health care providers lower key lab values.
Amgen today announced that the European Commission has granted marketing authorisation for Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis.
Parsabiv is the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the end of a haemodialysis session.
